세계의 소양증 치료제 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Pruritus Therapeutics Market reached USD 9.6 billion in 2024 and is projected to grow at a CAGR of 4.2% between 2025 and 2034. The rising incidence of chronic itching disorders, driven by conditions such as atopic dermatitis, psoriasis, and chronic kidney disease, continues to fuel market expansion. As pruritus remains a common yet often challenging symptom to treat, the demand for advanced therapeutic solutions is accelerating. The increasing burden of dermatologic and systemic conditions worldwide is compelling pharmaceutical companies to innovate and expand their treatment portfolios. The growing geriatric population, a demographic highly susceptible to chronic pruritus, further amplifies market demand. Additionally, heightened awareness regarding available treatments, coupled with improved access to healthcare services, is expected to drive sustained growth over the next decade.

Advancements in medical research are transforming the pruritus therapeutics landscape, with new drug classes such as biologics and JAK inhibitors offering promising results. These innovative treatments are reshaping the market by addressing underlying causes rather than just alleviating symptoms. Pharmaceutical firms are actively investing in research and development to introduce targeted therapies that provide long-term relief with minimal side effects. The rise of precision medicine and the expansion of clinical trials for pruritus-related conditions are creating new opportunities for industry players. With a growing emphasis on patient-centric care, companies are focusing on developing more effective, safer, and personalized treatment options.

The atopic dermatitis segment accounted for 35.7% of the global market share in 2024, driven by its high prevalence and the urgent need for targeted therapies. Chronic itching associated with atopic dermatitis significantly impacts quality of life, pushing patients and healthcare providers to seek more effective solutions. The development of novel medications, including non-steroidal treatments and biologic therapies, has been instrumental in expanding treatment options. Meanwhile, cholestatic pruritus, often linked to liver diseases, has further intensified the demand for effective therapeutics. The pruritus market continues to evolve, with new treatment indications and expanded access to advanced medications driving substantial growth.

Corticosteroids remain the leading product category in pruritus therapeutics, accounting for a significant market share. The corticosteroids segment was valued at USD 4 billion in 2024, cementing its role as a cornerstone treatment for various pruritic conditions. Widely recognized for their efficacy, corticosteroids are commonly used for conditions such as dermatitis and urticaria. Their availability in multiple formulations-including topical creams, oral medications, and injectables-ensures their adaptability for different patient needs. Their affordability and accessibility further reinforce their widespread use, particularly in regions where cost-effective treatment options are essential.

The U.S. Pruritus Therapeutics Market was valued at USD 3.6 billion in 2024, maintaining its dominance due to a high prevalence of chronic pruritus conditions and a well-established healthcare system. Strong research and development initiatives, coupled with a steady pipeline of innovative treatments, continue to propel market growth. The expansion of biologics, JAK inhibitors, and targeted therapies is enhancing treatment outcomes, while the rise of personalized medicine is reshaping patient care. With a growing focus on addressing the root causes of pruritus, the U.S. market is expected to remain at the forefront of therapeutic advancements, driving innovation and accessibility in the years to come.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of dermatological diseases
    • 3.2.1.2 Advancements in targeted therapies and biologics
    • 3.2.1.3 Increasing awareness and diagnosis rates
    • 3.2.1.4 Growing geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of biologic and targeted therapies
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Corticosteroids
• 5.3 Antihistamines
• 5.4 Counterirritants
• 5.5 Immunosuppressant
• 5.6 Calcineurin inhibitors
• 5.7 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Atopic dermatitis
• 6.3 Allergic contact dermatitis
• 6.4 Psoriasis
• 6.5 Urticaria
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Amgen
• 9.3 Astellas Pharma
• 9.4 Arcutis Biotherapeutics
• 9.5 Bristol-Myers Squibb
• 9.6 Cara Therapeutics
• 9.7 Eli Lilly And Company
• 9.8 GSK
• 9.9 Galderma
• 9.10 Johnson & Johnson
• 9.11 Kyowa Kirin
• 9.12 Novartis AG
• 9.13 Pfizer
• 9.14 Sanofi
• 9.15 Teva Pharmaceutical Industries